Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

7(th) International Immunoglobulin Conference: Interlaken Leadership Awards.
Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells.
Multiple Sclerosis: Progress, but No Cure.
Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.
Microglia Plasticity During Health and Disease: An Immunological Perspective.
Glial influences on BBB functions and molecular players in immune cell trafficking.
Are PrP(C)s involved in some human myelin diseases? Relating experimental studies to human pathology.
Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics.
[Treatment for multiple sclerosis in patients with collagen diseases].
Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted?
A single-group pilot feasibility study of cognitive behavioural therapy in people with multiple sclerosis with depressive symptoms.
Oropharyngeal dysphagia in multiple sclerosis.
Modeling the course and outcomes of MS is statistical twaddle-No.
Endocannabinoids and Endocannabinoid-Related Mediators: Targets, Metabolism and Role In Neurological Disorders.
Mechanisms of T2 * anisotropy and gradient echo myelin water imaging.
Helminth/Parasite treatment of multiple sclerosis.
Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study.
IgM to S-nitrosylated protein is found intrathecally in relapsing-remitting multiple sclerosis.
[Multiple sclerosis: a comprehensive treatment and rehabilitation].
[Visual neurorehabilitation of patients with cerebral damage using botulinum toxin].
TCR Transgenic Mice That Shed Light on Immune and Environmental Regulators in Multiple Sclerosis.
Central motor conduction time.
Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment.
Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry.

Pages